Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Abivax SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Abivax SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Abivax SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Abivax SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Evotec and Abivax Enter into Partnership 11
ABIVAX Enters into Co-Marketing Agreement with Finlay Institute 12
Licensing Agreements 13
ExpreS2ion Biotech to Enter into Licensing Agreement with Abivax 13
Heber Biotec Enters Into Licensing Agreement with Abivax 14
ABIVAX Enters into Licensing Agreement with CIGB for ABX203 15
Equity Offering 16
Abivax to Raise USD14 Million in Public Offering of Shares 16
Abivax Raises USD65 Million in IPO 17
Abivax SA – Key Competitors 18
Abivax SA – Key Employees 19
Abivax SA – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Sep 20, 2017: ABIVAX First-Half 2017 Financial Results and Update 21
Mar 15, 2017: ABIVAX Announces 2016 Full-Year Results and Progress Report 24
Sep 20, 2016: ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results 27
Mar 15, 2016: ABIVAX – 2015 Full-Year Results and Progress Report 29
Corporate Communications 31
Oct 05, 2017: ABIVAX expands Scientific Advisory Board with appointment of renowned virologist and former President of the Pasteur Institute, Prof. Christian Brechot 31
Dec 15, 2016: ABIVAX appoints Didier Blondel as Chief Financial Officer 32
Government and Public Interest 33
Jan 09, 2017: ABIVAX to receive €8.4 million from Bpifrance “Invest in the Future Program” (PIA) for the development of innovative antiviral drugs 33
Product News 34
11/22/2016: ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy 34
10/11/2016: ABIVAX Announces R&D Day at Company’s New Collaborative Laboratory in Montpellier 35
04/27/2016: ABIVAX Abstract on ABX464 Selected for Presentation at the AIDS 2016 Conference in Durban, South Africa 36
Feb 23, 2017: ABIVAX Has Discovered Novel Antiviral Molecules with Potential for Dengue Virus Treatment 37
Clinical Trials 38
Apr 04, 2017: ABIVAX initiates clinical trial (ABX464-005) to evaluate the effect of ABX464 on HIV-reservoirs in HIV Patients 38
Feb 02, 2017: Phase I Clinical Data of ABX464, ABIVAX’s First-in-Class anti-HIV Drug, Published in Two Articles in Peer-Reviewed Journals 39
Dec 08, 2016: ABIVAX Reports New Preclinical Data Supporting ABX464 as HIV Functional Cure and Novel Treatment for Inflammatory Diseases at HIV DART Meeting 40
Dec 06, 2016: ABIVAX provides update on clinical development program for ABX464 for functional cure of patients with HIV-infection 41
Nov 16, 2016: ABIVAX to Present Phase IIa Clinical Data on ABX464 during NIH/NIAID-Sponsored Strategies for an HIV Cure Meeting 2016 42
Oct 27, 2016: ABIVAX presented this week new pre-clinical data on ABX464 during scientific conference on “HIV Drug Therapy” in Glasgow, Scotland 43
Sep 13, 2016: ABIVAX Completes the Second Milestone in CaReNa, a “Strategic Industrial Innovation Project” Supported by Bpifrance 44
May 30, 2016: Ongoing Clinical Development of ABX464: ABIVAX Launches ABX464-004 Study 45
Apr 19, 2016: ABIVAX Obtains Regulatory and Ethics Clearance in Spain to Begin Second Phase IIa Clinical Trial For ABX464 In HIV/AIDS Patients 46
Jan 21, 2016: ABIVAX to present at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464 47
Jan 11, 2016: ABIVAX announces positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
Abivax SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Abivax SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Abivax SA, Deals By Therapy Area, 2011 to YTD 2017 9
Abivax SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Evotec and Abivax Enter into Partnership 11
ABIVAX Enters into Co-Marketing Agreement with Finlay Institute 12
ExpreS2ion Biotech to Enter into Licensing Agreement with Abivax 13
Heber Biotec Enters Into Licensing Agreement with Abivax 14
ABIVAX Enters into Licensing Agreement with CIGB for ABX203 15
Abivax to Raise USD14 Million in Public Offering of Shares 16
Abivax Raises USD65 Million in IPO 17
Abivax SA, Key Competitors 18
Abivax SA, Key Employees 19
Abivax SA, Other Locations 20